KeyBanc Capital Markets increased its price target for Lonza Group (LONN:SW) (OTC: LZAGY) shares to CHF 635 from CHF 610, ...

With the purchase of a former Lonza biologics plant now in the books, San Francisco-based CDMO Joinn Biologics is expanding from one Bay Area to another. Over the weekend, Joinn announced (Chinese ...

Lonza’s biologics segment accounted for 51% of its ... Due to the high switching costs, Lonza manufactures products for the entirety of their commercial life, which is often around 10 years.

Swiss Biotechnology firm Lonza, which purchased the Genentech facility in Vacaville last year, reported an income of 6.6 billion in Swiss francs (CHF) for the year 2024, which converts to about ...

Lonza Group Ltd (LONN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thibault ...

As of January 30 at 3:00:00 PM EST. Market Open. Lonza Group Ltd (LZAGF) reports stable revenue, robust cash flow, and outlines ambitious growth plans for 2025 amidst market challenges.

We think Lonza is well positioned to deliver strong performance, particularly in the fast-growing biologics and cell ... We sell different types of products and services to both investment ...

Deutsche Bank raised the firm’s price target on Lonza (LZAGY) to CHF 744 from CHF 645 and keeps a Buy rating on the shares.Maximize Your ...

including Lonza, Thermo Fisher and Catalent. But Korean powerhouse Samsung Biologics has somehow avoided the slide. The company has reported another robust increase in its top line, with a 23% ...